EB病毒阴性霍奇金淋巴瘤中的Th17免疫微环境:对免疫治疗的启示
该研究通过免疫组化和基因表达谱分析约翰霍普金斯档案库中32例经典型霍奇金淋巴瘤(12例EBV阳性、20例EBV阴性),发现EBV阳性肿瘤呈Th1型免疫特征,而EBV阴性肿瘤呈致病性Th17型并伴IL-23/IL-17轴持续激活。作者认为阻断IL-23/IL-17轴的药物可能增强抗PD-1治疗在EBV阴性经典型霍奇金淋巴瘤中的疗效。
要点
- EBV阳性经典型霍奇金淋巴瘤呈Th1型免疫特征,CD8+ T细胞浸润增加并协调表达Tbet、IFNG和IDO。
- EBV阴性经典型霍奇金淋巴瘤呈致病性Th17型,伴IL-23/IL-17轴持续激活及浸润淋巴细胞内磷酸化STAT3表达升高。
- 作者认为阻断IL-23/IL-17轴的药物可能增强抗PD-1治疗在EBV阴性经典型霍奇金淋巴瘤中的疗效。
核心结论
- EBV阳性与EBV阴性经典型霍奇金淋巴瘤呈现二分化的细胞与细胞因子免疫环境,EBV阴性肿瘤呈致病性Th17特征并伴IL-23/IL-17轴持续激活。
- 作者认为阻断IL-23/IL-17轴的药物可能增强抗PD-1治疗在EBV阴性经典型霍奇金淋巴瘤中的疗效。
研究设计与样本
- 采用免疫组化检测免疫细胞亚群和检查点分子,并结合基因表达谱分析,对约翰霍普金斯档案库中32例经典型霍奇金淋巴瘤(12例EBV阳性、20例EBV阴性)进行表征。
主要发现
- EBV阳性肿瘤呈Th1型特征,CD8+ T细胞浸润增加,并协调表达经典Th1转录因子Tbet(TBX21)、干扰素-γ(IFNG)及IFN-γ诱导的免疫抑制酶吲哚胺2,3-双加氧酶。
- EBV阴性肿瘤呈致病性Th17型特征,伴IL-23/IL-17轴持续激活,浸润淋巴细胞内磷酸化信号转导及转录激活因子3表达升高。
临床怎么用
- 作者认为阻断IL-23/IL-17轴的药物(已在临床用于治疗某些自身免疫性疾病)可能增强抗PD-1治疗在EBV阴性经典型霍奇金淋巴瘤中的疗效。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Classical Hodgkin lymphoma (CHL) is a neoplasm characterized by robust inflammatory infiltrates and heightened expression of the immunosuppressive PD-1/PD-L1 pathway. Although anti-PD-1 therapy can be effective in >60% of patients with refractory CHL, improved treatment options are needed for CHLs which are resistant to anti-PD-1 or relapse after this form of immunotherapy. A deeper understanding of immunologic factors in the CHL microenvironment might support the design of more effective treatment combinations based on anti-PD-1. In addition, because the Epstein-Barr virus (EBV) residing in some CHL tumors is strongly immunogenic, we hypothesized that characteristics of the tumor immune microenvironment in EBV+ CHL would be distinct from EBV- CHL, with specific implications for designing combination treatment regimens. Employing immunohistochemistry for immune cell subsets and checkpoint molecules, as well as gene expression profiling, we characterized 32 CHLs from the Johns Hopkins archives, including 12 EBV+ and 20 EBV- tumors. Our results revealed a dichotomous cellular and cytokine immune milieu in EBV+ vs EBV- CHL. EBV+ tumors displayed a T helper 1 (Th1) profile typical of effective antitumor immunity, with increased infiltration of CD8+ T cells and coordinate expression of the canonical Th1 transcription factor Tbet (TBX21), interferon-γ (IFNG), and the IFN-γ-inducible immunosuppressive enzyme indoleamine 2,3-dioxygenase. In contrast, EBV- tumors manifested a pathogenic Th17 profile and ongoing engagement of the interleukin-23 (IL-23)/IL-17 axis, with heightened phosphorylated signal transducer and activator of transcription 3 expression in infiltrating lymphocytes. These findings suggest that drugs blocking the IL-23/IL-17 axis, which are already in the clinic for treating certain autoimmune disorders, may enhance the therapeutic impact of anti-PD-1 therapy in EBV- CHL.
引用
- Duffield AS, Ascierto ML, Anders RA, et al. Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy. Blood Adv. 2017. PMID: 29296775. doi:10.1182/bloodadvances.2017007260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。